Efficient allocation of resources to prevent HIV infection among injection drug users: The Prevention Point Philadelphia (PPP) needle exchange program

Health Economics

Volumn 15, Issue 2, 2006, Pages 147-158

  Harris, Zoë K ^a,b  

^a YALE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

AIDS; Cost effectiveness; Density of injection drug users; Marginal cost per syringe; Needle exchange site location

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CASE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; PRIORITY JOURNAL; RESOURCE ALLOCATION; SYRINGE; UNITED STATES;

EFFICIENCY, ORGANIZATIONAL; HIV INFECTIONS; MODELS, STATISTICAL; NEEDLE-EXCHANGE PROGRAMS; PHILADELPHIA; RESOURCE ALLOCATION; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 32044447443     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.1021     Document Type: Article

References (56)

1. Kaplan EH. Economic analysis of needle exchange. AIDS 1995; 9: 1113-1119.
2. Kahn JG. The cost-effectiveness of HIV prevention targeting: how much more bang for the buck? Am J Public Health 1996; 86: 1709-1712.
3. Friedrich CM, Brandeau ML. Using simulation to find optimal funding levels for HIV prevention programs with different costs and effectiveness. In Proceedings of the 1998 Medical Simulation Conference, San Diego, CA, Anderson JG, Katzper M (eds). 1998.
4. Kaplan EH. Economic evaluation and HIV prevention community planning: a policy analyst's perspective. In Handbook of Economic Evaluation of HIV Prevention Programs, Holtgrave DR (ed.). Plenum Press: New York, 1998; 177-193.
5. Kaplan EH, Pollack H. Allocating HIV prevention resources. Socio-Econ Planning Sci 1998; 32: 257-263.
6. Lurie P, Gorsky R, Jones TS, Shomphe L. An economic analysis of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1): S126-S132.
7. Richter A, Brandeau ML, Owens DK. An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users and non-users. Med Decis Making 1999; 19: 167-179.
8. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001; 96: 1267-1278.
9. Rauner MS, Brandeau ML. AIDS policy modeling for the 21st century: an overview of key issues. Health Care Manage Sci 2001; 4: 165-180.
10. Zaric GS, Brandeau ML. Resource allocation for epidemic control over short time horizons. Math Biosci 2001; 171: 33-58.
11. Zaric GS, Brandeau ML. Optimal investment in a portfolio of HIV prevention programs. Med Decis Making 2001; 21: 391-408.
12. Holtgrave DR, Pinkerton SD, Merson M. Estimating the cost of unmet HIV-prevention needs in the United States. Am J Prev Med 2002; 23: 7-12.
13. Kaplan EH, Merson MH. Allocating HIV-prevention resources: balancing efficiency and equity. Am J Public Health 2002; 92: 1905-1907.
14. Rauner MS. Using simulation for AIDS policy modeling: benefits for HIV/ AIDS prevention policy makers in Vienna, Austria. Health Care Manage Sci 2002; 5: 121-134.
15. Brandeau ML, Zaric GS, Richter A. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis. J Health Econ 2003; 22: 575-598.
16. Cartwright WS, Solano PL. The economics of public health: financing drug abuse treatment services. Health Policy 2003; 66: 247-260.
17. Wilson AR, Kahn JG. Preventing HIV in injection drug users: choosing the best mix of interventions for the population. J Urban Health 2003; 80: 465-481.
18. Wilson AR, Kahn JG. Preventing HIV in injection drug users: exploring the tradeoffs between interventions. Socio-Econ Planning Sci 2003; 37: 269-288.
19. Perlman DC, Gourevitch MN, Trinh C, Salomon N, Horn L, Des Jarlais DC. Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program. J Urban Health 2001; 78: 550-567.
20. Perlman DC, Friedmann P, Horn L et al. Impact of monetary incentives on adherence to referral for screening chest X-rays after syringe exchange-based tuberculin skin testing. J Urban Health 2003; 80: 428-437.
21. Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health 2003; 80: 416-427.
22. Buchanan D, Shaw S, Teng W, Hiser P, Singer M. Neighborhood differences in patterns of syringe access, use, and discard among injection drug users: implications for HIV outreach and prevention education. J Urban Health 2003; 80: 438-454.
23. Robles RR, Colon HM, Matos TD et al. Syringe and needle exchange as HIV/ AIDS prevention for injection drug users in Puerto Rico. Health Policy 1998; 45: 209-220.
24. Strike CJ, Challacombe L, Myers T, Millson M. Needle exchange programs. Delivery and access issues. Can J Public Health 2002; 93: 339-343.
25. Robles RR, Colon HM, Freeman DH. Copping areas as sampling and recruitment sites for out-of-treatment crack and injection drug users. Drugs and Society 1993; 7: 91-105.
26. Kaplan EH. Probability models of needle exchange. Oper Res 1995; 43: 558-569.
27. Kaplan EH. Needles that kill: modeling human immunodeficiency virus transmission via shared drug injection equipment in shooting galleries. Rev Infect Dis 1989; 11: 289-298.
28. Kaplan EH, Heimer R. A circulation theory of needle exchange. AIDS 1994; 8: 567-574.
29. Kaplan EH, O'Keefe E. Let the needles do the talking! evaluating the New Haven needle-exchange. Interfaces 1993; 23: 7-26.
30. Prevention Point Philadelphia. About Us: http://www.critpath.org/ppp/aboutus.html, 2002.
31. Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992 to 1995. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 505-511.
32. Singer M, Stopka T, Siano C et al. The social geography of AIDS and hepatitis risk: qualitative approaches for assessing local differences in sterile-syringe access among injection drug users. Am J Public Health 2000; 90: 1049-1056.
33. Des Jarlais DC, Diaz T, Perlis T et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003; 157: 467-471.
34. Diaz T, Des Jarlais DC, Vlahov D et al. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health 2001; 91: 23-30.
35. Kral AH, Lorvick J, Edlin BR. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr 2000; 24: 162-167.
36. Camacho LM, Bartholomew NG, Joe GW, Simpson DD. Maintenance of HIV risk reduction among injection opioid users: a 12 month posttreatment follow-up. Drug Alcohol Depend 1997; 47: 11-18.
37. Carlson RG, Falck RS, Wang J, Siegal HA, Rahman A. HIV needle risk behaviors and drug use: a comparison of crack-smoking and nonsmoking injection drug users in Ohio. J Psychoactive Drugs 1999; 31: 291-297.
38. Carlson RG, Wang J, Siegal HA, Falck RS. A preliminary evaluation of a modified needle-cleaning intervention using bleach among injection drug users. AIDS Educ Prev 1998; 10: 523-532.
39. Koblin BA, McCusker J, Lewis BF, Sullivan JL. Racial/ethnic differences in HIV-1 seroprevalence and risky behaviors among intravenous drug users in a multisite study. Am J Epidemiol 1990; 132: 837-846.
40. Murray JM, Law MG, Gao Z, Kaldor JM. The impact of behavioral changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol 2003; 32: 708-714.
41. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr 1992; 5: 1116-1118.
42. Heimer R, Clair S, Teng W, Grau LE, Khoshnood K, Singer M. Effects of increasing syringe availability on syringe-exchange use and HIV risk: Connecticut, 1990-2001. J Urban Health 2002; 79: 556-570.
43. Latkin CA, Vlahov D, Anthony JC, Cohn S, Mandell W, Nelson KE. Needle-cleaning practices among intravenous drug users who share injection equipment in Baltimore, Maryland. Int J Addict 1992; 27: 717-725.
44. Siegel JE, Weinstein MC, Fineberg HV. Bleach programs for preventing AIDS among i.v. drug users: modeling the impact of HIV prevalence. Am J Public Health 1991; 81: 1273-1279.
45. Watters JK, Cheng YT, Lorvick JJ. Drug-use profiles, race, age, and risk of HIV infection among intravenous drug users in San Francisco. Int J Addict 1991; 26: 1247-1261.
46. Philadelphia Department of Public Health. AIDS Surveillance Quarterly Update, 30 June 2001; http:// www.phila.gov/health/units/aaco/pdf/AIDS_Surv_Q_June_2001.pdf, 2001.
47. US Centers for Disease Control. Drug-Associated HIV Transmission Continues in the United States. IDU 2002; http://www.cdc.gov/hiv/pubs/facts/idu.pdf
48. Cook C. Executive Director of Prevention Point Philadelphia: Personal Interview, 24 November, 2003.
49. Bencivengo M. Assistant Health Commissioner, Coordinating Office for Drug and Alcohol Abuse Programs (CODAAP), Philadelphia. Presentation, with Informal Question & Answer Session, in Course on 'Urban Health Systems', University of Pennsylvania, 17 November, 2003.
50. Prevention Point Philadelphia. Services and Schedules: Syringe Exchange Program Sites: http:// www.critpath.org/ppp/services.html, 2002.
51. University of Pennsylvania Center for Studies of Addiction. Prevention Point Philadelphia: Report of Services Provided For: 1st Quarter Fiscal Year 2003-2004. July, August, September, University of Pennsylvania, HIV Prevention Research, Philadelphia, 14 November, 2003.
52. University of Pennsylvania Center for Studies of Addiction. Prevention Point Philadelphia: Report of Services Provided For: Fiscal Year 2002-2003, University of Pennsylvania, HIV Prevention Research, Philadelphia, 24 July, 2003.
53. Philadelphia Department of Public Health. IDU (Injecting drug use). Map of AIDS Cases by Zip Code and Councilman District, as of 31 December, 2000; http://www.phila.gov/health/units/aaco/pdf/injdruguse.pdf, 2001.
54. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 2000; 90: 1100-1111.
55. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1): S133-S138.
56. Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet 1997; 349: 604-608.